← Leaderboards
Weizhong Cai
Angion Biomedica Corporation
$17,018,171
Attributed
$17,018,171
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.1M · FY2005–12$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$17,018,171 · 12
By mechanism
R44$15,485,983 · 7
R43$1,532,188 · 5
Top collaborators
No co-investigators on record.
Most similar at Angion Biomedica Corporation
Same institution · by research overlap
- Prakash Narayan$20,015,268
- Latha Paka$8,163,089
- Youzhi Tong$426,946
Others in their field
Top investigators on “Hepatocyte Growth Factor”
- Shelly Chi-Loo Lu · Cedars-Sinai Medical Center$14,795,908
- Prakash Narayan · Angion Biomedica Corporation$13,752,713
- Michael Olivier · Medical College Of Wisconsin$10,339,877
- Satdarshan Singh Monga · University Of Hawaii At Manoa$9,838,392
- George K Michalopoulos · University Of Pittsburgh At Pittsburgh$9,578,222
- Reza Zarnegar · University Of Pittsburgh At Pittsburgh$9,108,976
Research focus
Hepatocyte Growth FactorSmall MoleculePre-ClinicalClinical TrialsMimeticsInjuryProteinsSafetyDrug KineticsTissuesDoseProgramsCostUnited States National Institutes Of HealthKidneyHalf-LifeGenesGrantTranslational ResearchFundingBaseIn VivoToxicologyPhase I Clinical Trials
Grant awards (22)
Unique Clinical Study on DGF Using Paired Kidneys$664,710
R44 · FY2012 · DK · contact PI
LPA Antagonists for the Treatment of IPF$354,104
R43 · FY2012 · HL · contact PI
A Pilot Clinical Study in Acute STEMI$1,484,711
R44 · FY2011 · HL · contact PI
Phase I Clinical Study Using an Antifibrotic Drug$764,642
R44 · FY2011 · DK · contact PI
Unique Clinical Study on DGF Using Paired Kidneys$664,710
R44 · FY2011 · DK · contact PI
Safety and PK Study in Hepatic Impairment Patients$1,553,079
R44 · FY2010 · AA · contact PI
A Pilot Clinical Study in Acute STEMI$1,430,128
R44 · FY2010 · HL · contact PI
Pilot Clinical Study in Renal Transplantation$822,071
R44 · FY2010 · DK · contact PI
Phase I Clinical Study Using an Antifibrotic Drug$311,292
R44 · FY2010 · DK · contact PI
Safety and PK Study in Hepatic Impairment Patients$1,426,068
R44 · FY2009 · AA · contact PI
Pilot Clinical Study in Renal Transplantation$842,216
R44 · FY2009 · DK · contact PI
Phase I Study of BB3 in Dialysis Patients$290,570
R43 · FY2009 · DK · contact PI
Phase I Clinical Trial for BB3$82,000
R43 · FY2009 · HL · contact PI
Refanalin for lung preservation and transplantation$957,162
R44 · FY2008 · HL · contact PI
Phase I Clinical Trial for BB3$295,478
R43 · FY2008 · HL · contact PI
TGFb1 Receptor Inhibitors for Liver Fibrosis$255,501
R43 · FY2008 · DK · contact PI
Kidney Preservation for Transplantation$1,121,256
R44 · FY2007 · DK · contact PI
Refanalin for lung preservation and transplantation$254,535
R43 · FY2007 · HL · contact PI
Hepatic Growth Factor Mimetic for Liver Fibrosis$1,063,817
R44 · FY2005 · AA
Refanalin for Liver Transplantation$637,350
R44 · FY2005 · AA
Hepatic Growth Factor Mimetic for Liver Fibrosis$981,340
R44 · FY2004 · AA
Refanalin for Liver Transplantation$761,431
R44 · FY2004 · AA